ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Ernexa Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.98−0.11 (-5.26%)
Close on Oct 19, 2026
- Market cap
- $2.34M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2022 Ended Dec 31, 2022 | Mar 20, 2023 | After market close | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | Apr 15, 2022 | After market close | – | – | – |
| Q2 FY2021 Ended Jun 30, 2021 | Aug 17, 2021 | After market close | – | – | – |
| Q3 FY2020 Ended Sep 30, 2020 | Nov 13, 2020 | Before market open | – | – | – |
| Q2 FY2020 Ended Jun 30, 2020 | Aug 7, 2020 | Before market open | – | – | – |
| Q1 FY2020 Ended Mar 31, 2020 | May 19, 2020 | After market close | – | – | – |
| Q4 FY2019 Ended Dec 31, 2019 | Mar 17, 2020 | After market close | – | – | – |
| Q3 FY2019 Ended Sep 30, 2019 | Oct 30, 2019 | After market close | – | – | – |
| Q2 FY2019 Ended Jun 30, 2019 | Aug 9, 2019 | After market close | – | – | – |
| Q1 FY2019 Ended Mar 31, 2019 | May 13, 2019 | After market close | – | – | – |
| Q4 FY2018 Ended Dec 31, 2018 | Mar 20, 2019 | After market close | – | – | – |
| Q3 FY2018 Ended Sep 30, 2018 | Nov 7, 2018 | After market close | – | – | – |
Press releases
Announcements Ernexa Therapeutics filed with the SEC
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Announces Pricing of $10.5 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing
Material agreement · New financial obligation · Unregistered share sale · Executive or director change · Other events · EX-99.1 to Form 8-K
Eterna TherapeuticsInvestor Presentation August 2023 1 © Eterna Therapeutics
Regulation FD disclosure · EX-99.1 to Form 8-K